

GSK announces Board and Committee changes

21 July 2017 | News

Dr Glimcher is currently Professor of Medicine at Harvard Medical School and is CEO, President and an Attending Physician at the Dana-Farber Cancer Institute



GSK announced that Dr Laurie Glimcher has been appointed to the Board of the Company as a Non-Executive Director and has been deemed a Scientific and Medical Expert. She will join the Board on 1 September 2017.

Philip Hampton, Chairman of GlaxoSmithKline plc, said: "I am delighted Laurie is joining the Board. Laurie brings a wealth of expertise in scientific and medical innovation and public health which will be invaluable to GSK."

Dr Glimcher is currently Professor of Medicine at Harvard Medical School and is CEO, President and an Attending Physician at the Dana-Farber Cancer Institute.

In addition to a number of senior leadership positions held at both Harvard Medical School and Harvard School of Public Health, Dr Glimcher has also served as Stephen and Suzanne Weiss Dean and Professor of Medicine at Weill Cornell Medical College and as an Attending Physician at the New York Presbyterian Hospital/Weill Cornell Medical Center.

She is a member of the Blue Ribbon Panel Advisory Board of the National Cancer Institute and of the American Asthma Foundation and a Non-Executive Director of the Parker Institute for Cancer Immunotherapy and of the Waters Corporation, where she also serves on their Corporate Governance Committee.

Dr Glimcher recently decided to step down from the Board of Bristol-Myers Squibb Co (BMS) after serving for 20 years on its Board.

On joining the Board Dr Glimcher will become a member of the Board's Science and Audit & Risk Committees.